AJMC August 24, 2024
In this review, authors explain the supply chain issues of getting a life-saving treatment “vein to vein.”
When FDA approved the first chimeric antigen receptor (CAR) T-cell therapy in August 2017, experts hailed its arrival as leap forward for patients with certain blood cancers who had lost hope. According to data published in 2020,1 clinical trials for tisagenlecleucel, or tisa-cel (Kymriah) demonstrated 83% remission rates, and soon patients with leukemia and lymphoma who met the criteria were lining up to try this miracle treatment or one approved months later, axicabtagene ciloleucel (axi-cel, Yescarta).2
Yet, for the 7 years that CAR T-cell therapies have been approved, the number of patients treated has never kept pace with those who could benefit, according...
Today's Sponsors
Today's Sponsor